Time‐Restricted Feeding Improves Glucose Tolerance in Men at Risk for Type 2 Diabetes: A Randomized Crossover Trial

Obesity ◽  
2019 ◽  
Author(s):  
Amy T. Hutchison ◽  
Prashant Regmi ◽  
Emily N.C. Manoogian ◽  
Jason G. Fleischer ◽  
Gary A. Wittert ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
At Risk ◽  
Glucose Tolerance ◽  
Crossover Trial ◽  
Restricted Feeding ◽  
Randomized Crossover Trial

scholarly journals Diagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT?

2018 ◽  
Vol 179 (3) ◽  
pp. D1-D14 ◽  
Author(s):  
Marianne Andersen ◽  
Dorte Glintborg
Keyword(s):  
Type 2 Diabetes ◽  
At Risk ◽  
Glucose Tolerance ◽  
Polycystic Ovary ◽  
Normal Weight ◽  
Oral Glucose ◽  
Diagnostic Purpose ◽  
Glycemic Status

Polycystic ovary syndrome (PCOS) is common in premenopausal women. The majority of women with PCOS have insulin resistance and the risk of type 2 diabetes mellitus (T2D) is higher in women with PCOS compared to controls. In non-pregnant women with PCOS, glycemic status may be assessed by oral glucose tolerance test (OGTT), fasting plasma glucose (FPG) or HbA1c. OGTT has been reckoned gold standard test for diagnosing T2D, but OGTT is rarely used for diagnostic purpose in other non-pregnant individuals at risk of T2D, apart from PCOS. OGTT has questionable reproducibility, and high sensitivity of the 2-h glucose value is at the expense of relatively low specificity, especially regarding impaired glucose tolerance (IGT). Furthermore, lean women with PCOS are rarely diagnosed with T2D and only few percent of normal-weight women have prediabetes. Glycemic status is necessary at diagnosis and during follow-up of PCOS, especially in women with high risk of T2D (obesity, previous gestational diabetes (GDM)). We suggest that OGTT should be used in the same situations in PCOS as in other patient groups at risk of T2D. OGTT is indicated for diagnosing GDM; however, OGTT during pregnancy may not be indicated in lean women with PCOS without other risk factors for GDM.

Physical Activity is Strongly Inversely Related To Post-Challenge Plasma Glucose and Glycemic Spikes in a Risk Population for Type 2 Diabetes

Folia Medica ◽  
2013 ◽  
Vol 55 (2) ◽  
pp. 33-42 ◽  
Author(s):  
Theodora Temelkova-Kurktschiev ◽  
Tsvetan Stefanov ◽  
Carsta Koehler ◽  
Elena Henkel ◽  
Frank Schaper ◽  
...  
Keyword(s):  
Physical Activity ◽  
Risk Factors ◽  
Type 2 Diabetes ◽  
At Risk ◽  
Glucose Tolerance ◽  
Plasma Glucose ◽  
Cardiometabolic Risk ◽  
Post Challenge ◽  
The Relationship

ABSTRACT AIM: To examine the relationship between physical activity (PA) and various cardiometabolic risk factors during an oral glucose tolerance test (OGTT), including glycemic spikes (PGS) in individuals at risk for type 2 diabetes. SUBJECTS AND METHODS: A total of 949 middle-aged subjects from the Risk factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes (RIAD) trial aged 40-70 years were included in the present cross-sectional analysis. Standard 75 g OGTT was performed and blood was collected every 30 min for 2 hours for measurements of plasma glucose (PG) and other cardiometabolic risk factors. PA was assessed using interviewer-administered questionnaire. RESULTS: Post-challenge PGS and maximal PG (PGmax) during OGTT were significantly lower in individuals with high PA vs. individuals with low PA even after body mass index (BMI) adjustment (p = 0.026 and p = 0.035, respectively). In univariate analysis post-challenge PG 30, 60, 90, and 120 minutes, PGS and PGmax during OGTT were significantly inversely correlated to PA. This correlation was attenuated but remained significant after adjustment for BMI. Fasting PG and glycosylated hemoglobin were not correlated to PA. Significantly higher fasting and post-challenge insulin levels were found among subjects with low vs. subjects with medium (p < 0.05) and high PA (p < 0.05). Post-challenge C-peptide and proinsulin levels were significantly lower in participants with high vs. participants with low PA (p < 0.05 for all). The relationship between 2-h PG and PA was observed also in lean subjects and in subjects with normal fasting glucose. In multivariate analysis PA was a significant independent determinant of 2-h PG. CONCLUSION: We found a strong inverse relationship between PA and various post-challenge cardiometabolic parameters during OGTT, including glycemic spikes, in a population at risk for diabetes. This relationship was only partially dependent on BMI.

Abstract # P-5: Inclusion of Walnut in the Diets of Adults at Risk for Type 2 Diabetes and Their Dietary Pattern Changes: A Randomized, Controlled, Crossover Trial

2016 ◽  
Vol 22 ◽  
pp. 15-16
Author(s):  
Valentine Yanchou Njike ◽  
Niloufarsadat Yarandi ◽  
Paul Petraro ◽  
Rockiy G. Ayettey ◽  
Judith A. Treu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
At Risk ◽  
Dietary Pattern ◽  
Crossover Trial ◽  
Randomized Controlled

Elevated fasting triglycerides predict impaired glucose tolerance in adolescents at risk for type 2 diabetes

2006 ◽  
Vol 7 (4) ◽  
pp. 205-210 ◽  
Author(s):  
Kathy Love-Osborne ◽  
Nancy Butler ◽  
Dexiang Gao ◽  
Phil Zeitler
Keyword(s):  
Type 2 Diabetes ◽  
At Risk ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance

Resveratrol treatment does not reduce arterial inflammation in males at risk of type 2 diabetes: a randomized crossover trial

2021 ◽  
Author(s):  
Ellen Boswijk ◽  
Marlies de Ligt ◽  
Marie-Fleur J Habets ◽  
Alma M.A. Mingels ◽  
Wouter D. van Marken Lichtenbelt ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Adipose Tissue ◽  
Crossover Trial ◽  
Placebo Treatment ◽  
Fdg Uptake ◽  
Resveratrol Treatment ◽  
Randomized Crossover Trial ◽  
Arterial Inflammation ◽  
18F Fdg

Abstract Purpose Resveratrol has shown promising anti-inflammatory effects in in vitro and animal studies. We aimed to investigate this effect on arterial inflammation in vivo. Methods This was an additional analysis of a double-blind randomized crossover trial which included eight male subjects with decreased insulin sensitivity who underwent an 18F-fluoroxyglucose (18F-FDG) PET/CT after 34 days of placebo and resveratrol treatment (150 mg/day). 18F-FDG uptake was analyzed in the carotid arteries and the aorta, adipose tissue regions, spleen, and bone marrow as measures for arterial and systemic inflammation. Maximum target-to-background ratios (TBRmax) were compared between resveratrol and placebo treatment with the non-parametric Wilcoxon signed-rank test. Median values are shown with their interquartile range. Results Arterial 18F-FDG uptake was non-significantly higher after resveratrol treatment (TBRmax all vessels 1.7 (1.6–1.7)) in comparison to placebo treatment (1.5 (1.4–1.6); p=0.050). Only in visceral adipose tissue, the increase in 18F-FDG uptake after resveratrol reached statistical significance (p=0.024). Furthermore, CRP-levels were not significantly affected by resveratrol treatment (p=0.091). Conclusions Resveratrol failed to attenuate arterial or systemic inflammation as measured with 18F-FDG PET in subjects at risk of developing type 2 diabetes. However, validation of these findings in larger human studies is needed.

Sign in / Sign up

Export Citation Format

Share Document